Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts
April 26th, 2018
Orthotopic intracranial injection of tumor cells has been used in cancer research to study brain tumor biology, progression, evolution, and therapeutic response. Here we present fluorescence molecular tomography of tumor xenografts, which provides real-time intravital imaging and quantification of a tumor mass in preclinical glioblastoma models.
Overview
This article presents a preclinical brain tumor imaging model using fluorescence molecular tomography (FMT) to study glioblastoma. The method allows for non-invasive, real-time monitoring of tumor dynamics in vivo.
Key Study Components
Area of Science
- Neuroscience
- Cancer Research
- Imaging Techniques
Background
- Orthotopic intracranial injection of tumor cells is crucial for studying brain tumor biology.
- Fluorescence molecular tomography provides real-time imaging capabilities.
- This technique aids in understanding tumor progression and therapeutic responses.
- It can be applied to various xenograft models across different organs.
Purpose of Study
- To establish a preclinical model for imaging brain tumors.
- To investigate tumor aggressiveness and heterogeneity.
- To assess treatment responsiveness in glioblastoma models.
Methods Used
- Seeding glioblastoma cells in a culture dish for incubation.
- Transducing cells with lentivirus expressing a fluorescent protein.
- Monitoring tumors in vivo before, during, and after treatment.
- Utilizing FMT for quantitative analysis of tumor mass.
Main Results
- Successful establishment of a glioblastoma imaging model.
- Demonstration of non-invasive monitoring capabilities.
- Quantitative assessment of tumor dynamics over time.
- Potential for application in other xenograft models.
Conclusions
- FMT is a valuable tool for studying brain tumors in vivo.
- The method enhances understanding of tumor biology and treatment effects.
- Future applications may extend to various cancer research areas.
Frequently Asked Questions
Executive Industry Relevance
Fluorescence molecular tomography (FMT) enables non-invasive, quantitative monitoring of intracranial glioblastoma xenografts in immunocompromised mice, supporting preclinical evaluation of tumor dynamics and therapeutic response. By eliminating the need for exogenous imaging substrates and allowing longitudinal tracking of tumor burden, FMT reduces animal stress and improves reproducibility in oncology discovery workflows. This approach enhances target validation and lead identification by providing mechanistic insights into glioma aggressiveness and treatment effects in a disease-relevant microenvironment.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by quantifying tumor growth kinetics in orthotopic glioma models.
- Operational Value: Supports functional target validation through longitudinal imaging of fluorescence-labeled cell populations.
- Predictive Value: Facilitates preclinical de-risking by correlating fluorescence signal changes with genetic or pharmacological interventions.
Screening & Assay Development
- Assay Readiness: Generates standardized, quantitative tumor mass measurements suitable for high-content screening platforms.
- Reproducibility: Cell pre-labeling with near-infrared fluorescent proteins ensures consistent signal detection across experimental cohorts.
- Scalability: Compatible with multi-organ xenograft models, enabling cross-tumor target validation.
Translational & Preclinical Research
- Disease Relevance: Intracranial delivery models the native brain microenvironment, improving translational fidelity of glioma studies.
- Biomarker Alignment: Fluorescent signal serves as a pharmacodynamic readout for target engagement in SHRNA-mediated knockdown studies.
- Risk-Adjusted Advancement: Enables go/no-go decisions based on tumor growth inhibition or progression over time.
Pipeline & Workflow Integration
FMT integrates into the discovery continuum from target validation through lead optimization, providing quantitative imaging readouts that inform preclinical progression decisions in neuro-oncology programs.
- Discovery Biology: Supports mechanistic de-risking by visualizing tumor heterogeneity and response to pathway-modulating agents.
- Screening: Delivers standardized tumor burden metrics for compound library screening in glioma models.
- Analytics: Enables statistical comparison of tumor volume changes across treatment groups using threshold-based region-of-interest analysis.
- Translational Research: Maintains continuity from in vitro validation to in vivo efficacy testing in orthotopic xenografts.
- Enterprise Reuse: Adaptable to diverse xenograft systems, promoting platform-wide standardization in oncology imaging.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in glioma models through direct, non-invasive tumor visualization.
- Operational Value: Eliminates repeated animal handling and substrate injection, improving workflow efficiency and animal welfare.
- Strategic Value: Improves portfolio triage by enabling early detection of ineffective therapeutics.
- Portfolio Impact: Supports risk-adjusted advancement by quantifying treatment-induced tumor regression or progression.
Implementation Considerations
- Requires expertise in stereotactic intracranial injection and fluorescent cell line engineering.
- Dependent on access to fluorescence molecular tomography imaging systems with appropriate near-infrared detection.
- Necessitates standardized cell sorting and lentiviral transduction protocols for consistent signal expression.
- Limited sensitivity for detecting sub-millimeter tumor masses, constraining early-stage intervention studies.
- Requires cross-functional alignment between imaging, pharmacology, and pathology teams for data interpretation.
Biopharma FAQs
Chapters in this video
0:05
Title
0:55
Construct-positive Glioblastoma Cell Sorting
2:46
Near-infrared Fluorescent Protein (iRFP)-tagged Glioblastoma Cell Intracranial Injection
4:49
Fluorescence Molecular Tomography (FMT) Imaging and Analysis
6:22
Results: Representative In Vivo FMT Imaging of Glioblastoma Xenografts
7:27
Conclusion
